Multiple studies highlighted that patients with hematological malignancies receiving immunosuppressive therapies such as stem cell transplantation, anti-CD20 therapies, Bruton’s tyrosine kinase (BTK) inhibitors and CAR-T cell treatments are at higher risk. The gene discussed is BTK; the disease is hematologic disorder.